| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10485096 | Value in Health | 2016 | 9 Pages |
Abstract
Current Medicaid policies restricting hepatitis C treatment to patients with advanced disease are more costly and less effective than unrestricted, full-access strategies. Collaboration between state and federal payers may be needed to realize the full public health impact of recent innovations in hepatitis C treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Alexis P. PhD, MSPH, Cindy L. PhD, Julie M. PhD, Michael J. MD, MSc, Douglas P. PhD, Larissa PhD, Shari S. MD, MPH, Galen E. PhD, Allan MD, Kenneth J. MD, MS,